Hemostemix is Up-Listing in the USA to Generate Liquidity
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) has announced its application to up-list to the OTCQB Venture Market to increase liquidity across USA, European, and Canadian markets. The company is promoting its ACP-01 therapy through social media, highlighting successful patient treatments for limb salvation, heart function regeneration, and vascular dementia.
Clinical results show significant efficacy: 83% of patients in a Phase II trial experienced healing of ulcers and resolution of ischemic rest pain over 4.5 years. In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment. The Phase II results demonstrated ulcer size reduction from 1.46 cm² to 0.48 mm² within three months (p = 0.01).
The company addresses a significant market, with 236 million people suffering from peripheral arterial disease, of which 23 million develop chronic limb threatening ischemia with a 60% five-year mortality rate.
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ha annunciato la sua richiesta di iscrizione al OTCQB Venture Market per aumentare la liquidità nei mercati degli Stati Uniti, europei e canadesi. La compagnia sta promuovendo la sua terapia ACP-01 attraverso i social media, evidenziando trattamenti riusciti per la salvaguardia degli arti, la rigenerazione della funzione cardiaca e la demenza vascolare.
I risultati clinici mostrano un'efficacia significativa: l'83% dei pazienti in uno studio di Fase II ha riportato la guarigione di ulcere e la risoluzione del dolore ischemico a riposo nell'arco di 4,5 anni. Nei pazienti con cardiomiopatia dilatativa, la funzione cardiaca è migliorata fino al 47,1% dopo un trattamento. I risultati della Fase II hanno dimostrato una riduzione delle dimensioni delle ulcere da 1,46 cm² a 0,48 mm² entro tre mesi (p = 0,01).
La compagnia si rivolge a un mercato significativo, con 236 milioni di persone affette da malattia arteriosa periferica, di cui 23 milioni sviluppano ischemia cronica agli arti con un tasso di mortalità del 60% entro cinque anni.
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ha anunciado su solicitud para listar en el OTCQB Venture Market para aumentar la liquidez en los mercados de EE. UU., Europa y Canadá. La compañía está promocionando su terapia ACP-01 a través de las redes sociales, destacando tratamientos exitosos para la salvación de extremidades, la regeneración de la función cardíaca y la demencia vascular.
Los resultados clínicos muestran una eficacia significativa: el 83% de los pacientes en un ensayo de Fase II experimentaron curación de úlceras y resolución del dolor isquémico en reposo durante 4.5 años. En pacientes con cardiomiopatía dilatada, la función cardíaca mejoró hasta en un 47.1% después de un tratamiento. Los resultados de la Fase II demostraron una reducción del tamaño de las úlceras de 1.46 cm² a 0.48 mm² en tres meses (p = 0.01).
La compañía aborda un mercado significativo, con 236 millones de personas que sufren de enfermedad arterial periférica, de las cuales 23 millones desarrollan isquemia crónica que amenaza las extremidades con una tasa de mortalidad del 60% en cinco años.
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF)는 OTCQB 벤처 마켓로 상장하기 위한 신청을 발표했으며, 이는 미국, 유럽, 캐나다 시장에서의 유동성을 증가시키기 위함입니다. 회사는 소셜 미디어를 통해 ACP-01 치료법을 홍보하고 있으며, 사지 구제, 심장 기능 재생, 혈관성 치매에 대한 성공적인 환자 치료를 강조하고 있습니다.
임상 결과는 상당한 효능을 보여줍니다: 83%의 환자가 4.5년 동안 궤양 치유 및 허혈성 안정통증의 해소를 경험했습니다. 확장형 심근병 환자에서는 치료 후 심장 기능이 최대 47.1% 개선되었습니다. 2상 결과는 궤양 크기가 1.46 cm²에서 0.48 mm²로 3개월 이내에 감소했음을 보여줍니다 (p = 0.01).
회사는 2억 3600만 명의 사람들이 말초 동맥 질환으로 고통받고 있으며, 이 중 2300만 명은 5년 사망률이 60%인 만성 사지 위협 허혈을 발전시키고 있는 중대한 시장을 다루고 있습니다.
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) a annoncé sa demande de cotation sur le OTCQB Venture Market afin d'augmenter la liquidité sur les marchés américains, européens et canadiens. L'entreprise promeut sa thérapie ACP-01 via les réseaux sociaux, mettant en avant des traitements réussis pour la préservation des membres, la régénération de la fonction cardiaque et la démence vasculaire.
Les résultats cliniques montrent une efficacité significative : 83% des patients dans un essai de Phase II ont connu la guérison des ulcères et la résolution de la douleur ischémique au repos sur 4,5 ans. Chez les patients atteints de cardiomyopathie dilatée, la fonction cardiaque s'est améliorée jusqu'à 47,1% après un traitement. Les résultats de la Phase II ont démontré une réduction de la taille des ulcères de 1,46 cm² à 0,48 mm² en trois mois (p = 0,01).
L'entreprise s'adresse à un marché significatif, avec 236 millions de personnes souffrant de maladie artérielle périphérique, dont 23 millions développent une ischémie chronique menaçant les membres avec un taux de mortalité de 60% sur cinq ans.
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) hat seine Bewerbung zur Notierung im OTCQB Venture Market angekündigt, um die Liquidität in den Märkten der USA, Europas und Kanadas zu erhöhen. Das Unternehmen fördert seine ACP-01-Therapie über soziale Medien und hebt erfolgreiche Patientenbehandlungen zur Rettung der Gliedmaßen, zur Regeneration der Herzkraft und zur vaskulären Demenz hervor.
Klinische Ergebnisse zeigen eine signifikante Wirksamkeit: 83% der Patienten in einer Phase-II-Studie erfuhren innerhalb von 4,5 Jahren eine Heilung von Geschwüren und die Auflösung von ischämischen Ruhe-Schmerzen. Bei Patienten mit dilatativer Kardiomyopathie verbesserte sich die Herzfunktion um bis zu 47,1% nach einer Behandlung. Die Ergebnisse der Phase II zeigten eine Verringerung der Geschwürgröße von 1,46 cm² auf 0,48 mm² innerhalb von drei Monaten (p = 0,01).
Das Unternehmen bedient einen signifikanten Markt, in dem 236 Millionen Menschen an peripherer arterieller Erkrankung leiden, von denen 23 Millionen eine chronische, extrem bedrohliche Ischämie entwickeln, mit einer fünfjährigen Sterblichkeitsrate von 60%.
- Application for OTCQB up-listing to increase market accessibility and liquidity
- Phase II trial showed 83% success rate in treating ulcers and ischemic rest pain
- Cardiac function improved up to 47.1% in cardiomyopathy patients after single treatment
- Significant ulcer size reduction demonstrated in Phase II results (p = 0.01)
- None.
Calgary, Alberta--(Newsfile Corp. - January 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has applied to up-list its shares on the OTCQB Venture Market. Currently listed on the TSXV Exchange, Frankfurt, and the OTC, Hemostemix aims to increase its liquidity by broadening its reach to all investors who trade in the capital markets of the USA, Europe, and Canada.
The Company's social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X, describe the patients' treatment results in their own words. Individual patients describe how the Hemostemix therapy, ACP-01, saved their limb from amputation, regenerated their heart function, successfully treated congestive heart failure, and overcame vascular dementia. These outcomes highlight Hemostemix as an investment opportunity.
"Our testimonials connect ACP-01-treated with the millions of no-option patients who may obtain an ACP treatment under special access program," stated Thomas Smeenk, CEO. "For example, 236 million suffer from peripheral arterial disease. 23 million degenerate into chronic limb threatening ischema ("CLTI"), and face a
Before Treatment
Cannot view this image? Visit:
https://images.newsfilecorp.com/files/5065/235778_6910c01b4421da8b_002full.jpg
After Treatment with Hemostemix ACP-01
Cannot view this image? Visit:
https://images.newsfilecorp.com/files/5065/235778_6910c01b4421da8b_004full.jpg
Precision Healthcare (ACP-01) Restores Quality of Life
ACP-01 is sourced from the patient's blood and cultured in the patient's serum. It is demonstrated to be safe and statistically effective. For example:
In dilated cardiomyopathy patients, cardiac function as measured by left ventricle ejection fraction percent (LVEF%) increased by up to
47.1% following one treatment (Stem Cell Research & Therapy, November 2023), with the most marked improvements observed in patients with severe dilated cardiomyopathy (LVEF% <20% ).The Company's published phase II results detailed that ulcer size decreased significantly in the treated group from a mean of 1.46 cm² to 0.48 mm², p = 0.01 within three months (Journal of Biomedical Research & Environmental Science, February 2024).
Follow Hemostemix:
- Instagram: https://www.instagram.com/hemostemix.inc?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
- Facebook: https://www.facebook.com/profile.php?id=61571076998595
- LinkedIn: https://www.linkedin.com/in/thomas-smeenk-03b9213/
- YouTube: https://www.youtube.com/@hemostemix3830
- X: @heartrepairguy
About Hemostemix
Founded in 2003, Hemostemix is a clinical-stage biotechnology company and winner of the World Economic Forum Technology Pioneer Award. The Company has developed and patented a blood-based stem cell therapeutics platform that includes angiogenic cell precursors (ACP), neuronal cell precursors (NCP), and cardiomyocyte cell precursors (CCP)
For more information, visit www.hemostemix.com.
For further information, please contact:
Thomas Smeenk, President & CEO
Email: tsmeenk@hemostemix.com
Phone: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program, and social media programs targeted to generate sales. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235778
FAQ
What are the clinical results of Hemostemix (HMTXF) ACP-01 therapy for cardiac patients?
What is the success rate of HMTXF's Phase II trial for peripheral arterial disease?
How effective is HMTXF's ACP-01 treatment in reducing ulcer size?
What is the market potential for Hemostemix (HMTXF) ACP-01 therapy?
Why is Hemostemix (HMTXF) applying for OTCQB up-listing?
